Meeting
2021 Genitourinary Cancers Symposium
A phase Ib single-arm study of bintrafusp alfa for the treatment of pretreated, locally advanced/unresectable or metastatic urothelial cancer.
Authors
Petros Grivas
Division of Oncology, Department of Medicine, University of Washington, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, WA
Petros Grivas , Rafael Morales-Barrera , Srikala S. Sridhar , Yohann Loriot , Michiel Simon Van Der Heijden , Matt D. Galsky , Dawn Baxter , Ahmed Hussein Khaled , Bruce A. Hug
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04349280
Citation
J Clin Oncol 39, 2021 (suppl 6; abstr TPS501)
DOI
10.1200/JCO.2021.39.6_suppl.TPS501
Abstract #
TPS501
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Impact of renal impairment on clinical outcomes in patients (pts) with locally advanced or metastatic (LA/M) urinary tract carcinoma (UTC) treated with atezolizumab (atezo): Analysis of the international SAUL study.
First Author: Margitta Retz
First Author: Igor Tsaur
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Tislelizumab plus chemotherapy (chemo) versus placebo plus chemo as first-line treatment for locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: RATIONALE-305 European/North American patient subgroup.
First Author: Hendrik-Tobias Arkenau
Poster
2023 ASCO Genitourinary Cancers Symposium
Enfortumab vedotin (EV) alone or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer (la/mUC): Subgroup analyses of confirmed objective response rate (cORR) from EV-103 cohort K.
First Author: Peter H. O'Donnell